Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A landmark moment for pediatric cardiology: the FDA has approved mavacamten (Camzyos) for children and adolescents with obstructive hypertrophic cardiomyopathy (HCM) weighing at least 30 kg — making it the first FDA-approved drug specifically designed to treat cardiomyopathy in kids. The approval was backed by the SCOUT-HCM trial, which showed the drug outperformed placebo in reducing a key cardiac obstruction measure in patients aged 12 to 17.
A first for pediatric cardiology
The FDA has expanded its approval of mavacamten (Camzyos) to include pediatric patients with obstructive hypertrophic cardiomyopathy (HCM) who weigh at least 30 kg (~66 lbs). Originally approved in 2022 for adults, this marks the first time an FDA-approved medication has been specifically indicated for cardiomyopathy treatment in children — a milestone described as "a game changer for the field" by Dr. Joseph W. Rossano of Children's Hospital of Philadelphia, who chaired the SCOUT-HCM trial steering committee.
The approval was based on results from the SCOUT-HCM trial, which demonstrated that mavacamten was superior to placebo in reducing the Valsalva left ventricular outflow tract (LVOT) gradient at 28 weeks in patients aged 12 to 17. The drug also showed a strong safety profile in this younger population.
Key Takeaways:
Why it matters: Many pediatric HCM patients previously faced surgical intervention as a primary option. Mavacamten offers a non-surgical alternative that could delay or even eliminate the need for surgery — a potentially life-changing development for young patients and their families.
